Published in Cancer Treat Rep on March 01, 1984
Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. Br J Cancer (1985) 0.86
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer (1996) 0.78
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (1975) 10.04
Primary bioassay of human tumor stem cells. Science (1977) 9.69
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
High speed scintillation autoradiography. Science (1975) 5.15
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood (2000) 2.87
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
Primary bioassay of human myeloma stem cells. J Clin Invest (1977) 2.25
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest (1970) 2.21
B-cell neoplasia in man. Lancet (1974) 2.11
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol (1999) 2.05
Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med (1979) 1.94
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
"Sandwich" solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol (1969) 1.74
Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med (1990) 1.72
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol (1996) 1.57
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys (1998) 1.56
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Extraosseous multiple myeloma: imaging features. AJR Am J Roentgenol (1993) 1.52
2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52
Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer (1980) 1.52
Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res (1977) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. Cancer Res (1979) 1.51
Plasma cell granuloma of the nasal cavity treated by radiation therapy. Cancer (1991) 1.45
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol (1993) 1.44
Melphalan therapy for plasma cell myeloma. Blood (1968) 1.43
Myeloperoxidase deficiency. Immunologic study of a genetic leukocyte defect. N Engl J Med (1970) 1.41
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood (1991) 1.40
Immunology of the lower respiratory tract. II. The plaque-forming response of canine lymphoid tissues to sheep erythrocytes after intrapulmonary or intravenous immunization. J Clin Invest (1974) 1.39
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1990) 1.39
Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest (1991) 1.39
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer (1975) 1.39
Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest (1972) 1.38
Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood (1988) 1.36
Combination chemotherapy for multiple myeloma. Cancer (1972) 1.36
Localized and indolent myeloma. Blood (1980) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep (1984) 1.30
Immunoglobulin synthesis and tumour cell number and the natural history of multiple myeloma. Br Med J (1971) 1.30
The treatment of plasma cell myeloma. Adv Cancer Res (1967) 1.30
Prognostic factors in multiple myeloma. Cancer (1975) 1.29
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29
Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med (1982) 1.27
Application of a human tumor colony-forming assay to new drug screening. Cancer Res (1985) 1.26
Plasma cell myeloma--new biological insights and advances in therapy. Blood (1989) 1.25
The growth fraction of human myeloma cells. Blood (1981) 1.24
Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response? N Engl J Med (1971) 1.24
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst (1992) 1.23
Unmaintained remissions in multiple myeloma. Blood (1978) 1.22
Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. J Clin Oncol (1985) 1.20
Curability of solitary bone plasmacytoma. J Clin Oncol (1992) 1.20
CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant (2009) 1.19
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol (1986) 1.19
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (2010) 1.18
High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med (1989) 1.18
Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood (1980) 1.18
Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol (1973) 1.17
Nonsecretory multiple myeloma. Am J Hematol (1982) 1.17
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood (1993) 1.16
Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood (1987) 1.15
Immunology of the lower respiratory tract. Functional properties of bronchoalveolar lymphocytes obtained from the normal canine lung. J Clin Invest (1973) 1.15
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood (1987) 1.15
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (2007) 1.14
Polyamines as predictors of success and failure in cancer chemotherapy. Lancet (1975) 1.14
Inhibition of human melanoma colony formation by retinoids. Cancer Res (1979) 1.13
Prognostic features of asymptomatic multiple myeloma. Br J Haematol (1997) 1.13
Lymphocyte stimulation: selective destruction of cells during blastogenic response to transplantation antigens. Science (1971) 1.13
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol (2005) 1.13
Risk of disease progression in asymptomatic multiple myeloma. Am J Med (1993) 1.12
Plasma cell karyotype in multiple myeloma. Blood (1988) 1.11
Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med (1999) 1.11
Hydrolysis and protein binding of melphalan. J Pharm Sci (1978) 1.10
Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol (1995) 1.08